• XtalPi published annual report for year ended Dec. 31, 2025, marking first full-year profit as business shifted from project services toward platform licensing and co-development.
• AI for Science platform scaled as multi-agent systems drove more than 10,000 compound synthesis experiments per week, tightening closed-loop workflow across AI models and robotic labs.
• Drug discovery business expanded on antibody momentum, supported by platform partnerships including Eli Lilly deal valued at USD 345 million.
• International footprint broadened through 2025 acquisition of Liverpool ChiroChem, integrating automated chiral chemistry into AI- and robotics-driven R&D platform.
• Balance sheet positioned for continued investment as cash balance reached RMB 7.1 billion at end-2025, followed by RMB 2.5 billion net proceeds from new convertible bonds issued in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260417-12110861), on April 17, 2026, and is solely responsible for the information contained therein.